Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019643 · ClinicalTrials.gov registry record
Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer
A clinical trial, sponsored by National Institutes of Health Clinical Center (CC).
- Terminated
- Registry status
- 26
- Enrollment target
NCT00019643: Clinical Trial study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00019643 is a clinical trial that was terminated before completion, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019643 was terminated before completion, sponsored by National Institutes of Health Clinical Center (CC).
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Chemotherapy may affect various factors that can lead to weight gain. PURPOSE: Clinical trial to evaluate factors that may affect weight gain in women receiving adjuvant chemotherapy for stage I, stage II, or stage IIIA breast cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 1999-08 |
| Est. Completion | 2007-04 |
Why NCT00019643 stopped before completion
NCT00019643 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00019643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019643 about?
NCT00019643 is a clinical study titled "Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer". RATIONALE: Chemotherapy may affect various factors that can lead to weight gain. PURPOSE: Clinical trial to evaluate factors that may affect weight gain in women receiving adjuvant chemotherapy for stage I, stage II, or stage IIIA breast cancer.
What is the current status of trial NCT00019643?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 1999-08. Estimated completion is 2007-04.
Who is sponsoring clinical trial NCT00019643?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia